Orchid Pharma signs licensing and supply agreement with Libra for Exblifep across nine Latin American markets
Orchid Pharma has signed a licensing and supply agreement with Laboratorio Libra S.A. covering Exblifep (cefepime/enmetazobactam) across nine Latin American markets, announced on 24 October 2026.
By ScoutQuest · · 1 min read
- Potential Commercial Opportunity
- approximately USD 80 million over the first 10 years
- Exclusive Markets
- Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Panama, Paraguay and Uruguay
- Regulatory Approvals
- approvals from both the U.S. Food and Drug Administration and the European Medicines Agency
- Release
- Deal / acquisition
📌 Under the agreement, Libra receives exclusive rights to register, import and market Exblifep in Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Panama, Paraguay and Uruguay, while Orchid Pharma manufactures and supplies the finished dosage form.
📌 Orchid Pharma says the partnership is expected to represent a potential commercial opportunity of approximately USD 80 million over the first 10 years, based on projected demand across these markets.
📌 The company says commercialization in each market is subject to approval by the relevant national regulatory authority.
📌 Orchid Pharma says Exblifep holds approvals from both the U.S. Food and Drug Administration and the European Medicines Agency and is the first new chemical entity invented by an Indian pharmaceutical company to secure both approvals.
Also from Orchid Pharma
Board approves enabling resolution to explore raising up to Rs. 600 Crores
20 Oct 2026
Board approves enabling resolution to explore raising up to Rs. 600 crore
20 Oct 2026
Board meeting on October 20, 2026 to consider and evaluate options for raising funds
15 Oct 2026
More numbers
- Potential commercial opportunity over first 10 yearsapproximately USD 80 million
- Partnership period for the commercial opportunity10 years
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.